Placebo inhalation powder

DRUG5 trials

Sponsors

GlaxoSmithKline, Savara Inc., Boehringer Ingelheim, Actavis Inc.

Conditions

AsthmaCystic FibrosisMRSAPulmonary Disease, Chronic Obstructive

Phase 2

Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients

CompletedNCT01746095

Savara Inc.Cystic Fibrosis

Start: 2013-03-31End: 2014-11-30Updated: 2020-01-13

Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) Patients

CompletedNCT02172352

Boehringer IngelheimPulmonary Disease, Chronic Obstructive

Start: 1998-07-31Updated: 2014-06-24

Phase 3

Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) Axis

CompletedNCT01086410

GlaxoSmithKlineAsthma

Start: 2010-03-31End: 2010-09-30Updated: 2017-01-18

AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis

CompletedNCT03181932

Savara Inc.Cystic Fibrosis, MRSA

Start: 2017-09-20End: 2021-01-15Updated: 2022-12-16

Therapeutic Equivalence of Two Formulations of Fluticasone Propionate and Salmeterol Inhalation Powder in Subjects With Asthma

CompletedNCT03756883

Actavis Inc.Asthma

Start: 2018-12-03End: 2019-11-10Updated: 2021-09-24